Literature DB >> 28001098

Pre-eclampsia and risk of subsequent hypertension: in an American Indian population.

Lyle G Best1, Laramie Lunday2, Elisha Webster2, Gilbert R Falcon2, James R Beal2.   

Abstract

BACKGROUND AND OBJECTIVES: Pre-eclampsia (PE) shares a number of proposed pathophysiologic mechanisms related to those implicated in cardiovascular disease (CVD), such as endothelial dysfunction, inflammation, insulin resistance, and impaired renal regulation. PE has also been associated with subsequent hypertension, CVD, and related mortality in later life.
METHODS: At follow-up, the four most recent blood pressures, body mass index (BMI), and use of hypertensive medications were recorded from clinic visits of 130 PE cases and 289 normal pregnancies. Student's t test, Chi-square testing, multivariate linear, and logistic regression were used in analysis.
RESULTS: Follow-up measurements occurred a mean of 13.11 years post PE pregnancy. Multivariate linear regression showed a significant and independent association between current systolic blood pressure and previous history of PE (β = 4.47, p = 0.04), while adjusting for age, BMI, and blood pressure from 1 year prior to and up to the 20th week of gestation. A similarly adjusted multivariate logistic regression model found an odds ratio of 3.43, 95% CI 1.83-6.43, p = 0.001 for subsequent hypertension. Logistic regression analysis of the quartile with follow-up of less than 7.19 years also shows independent association of prior PE with subsequent hypertension. DISCUSSION AND
CONCLUSIONS: PE appears to confer risk of subsequent hypertension on this cohort of American Indian women within as little as 8 years. This risk is independent of additional risk factors such as increased age, BMI, and blood pressure prior to 20 weeks of gestation. There is evidence of increased risk among those with more severe PE.

Entities:  

Keywords:  Case–control study; hypertension; multivariable analysis; preeclampsia

Mesh:

Year:  2016        PMID: 28001098      PMCID: PMC6097877          DOI: 10.1080/10641955.2016.1250905

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  30 in total

Review 1.  Epidemiology of preeclampsia: impact of obesity.

Authors:  Arun Jeyabalan
Journal:  Nutr Rev       Date:  2013-10       Impact factor: 7.110

2.  What happens to women with preeclampsia? Microalbuminuria and hypertension following preeclampsia.

Authors:  R A North; D Simmons; D Barnfather; M Upjohn
Journal:  Aust N Z J Obstet Gynaecol       Date:  1996-08       Impact factor: 2.100

3.  Association of maternal endothelial dysfunction with preeclampsia.

Authors:  J C Chambers; L Fusi; I S Malik; D O Haskard; M De Swiet; J S Kooner
Journal:  JAMA       Date:  2001-03-28       Impact factor: 56.272

4.  Preeclampsia is associated with persistent postpartum cardiovascular impairment.

Authors:  Karen Melchiorre; George Ross Sutherland; Marco Liberati; Basky Thilaganathan
Journal:  Hypertension       Date:  2011-08-15       Impact factor: 10.190

5.  Hypertension in pregnancy.

Authors:  Marshall D Lindheimer; Sandra J Taler; F Gary Cunningham
Journal:  J Am Soc Hypertens       Date:  2010 Mar-Apr

6.  Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004.

Authors:  Anne B Wallis; Audrey F Saftlas; Jason Hsia; Hani K Atrash
Journal:  Am J Hypertens       Date:  2008-03-13       Impact factor: 2.689

Review 7.  Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis.

Authors:  Leanne Bellamy; Juan-Pablo Casas; Aroon D Hingorani; David J Williams
Journal:  BMJ       Date:  2007-11-01

Review 8.  Pre-eclampsia and cardiovascular disease.

Authors:  Christina W Chen; Iris Z Jaffe; S Ananth Karumanchi
Journal:  Cardiovasc Res       Date:  2014-02-13       Impact factor: 10.787

Review 9.  The global impact of pre-eclampsia and eclampsia.

Authors:  Lelia Duley
Journal:  Semin Perinatol       Date:  2009-06       Impact factor: 3.300

10.  Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors.

Authors:  Elisabeth B Magnussen; Lars J Vatten; George Davey Smith; Pål R Romundstad
Journal:  Obstet Gynecol       Date:  2009-11       Impact factor: 7.661

View more
  6 in total

1.  Effect of nicotine on placental ischemia-induced complement activation and hypertension in the rat.

Authors:  Connor F Laule; Cameron R Wing; Evan J Odean; Jacob A Wilcox; Jeffrey S Gilbert; Jean F Regal
Journal:  J Immunotoxicol       Date:  2017-12       Impact factor: 3.000

Review 2.  The Complement System and Preeclampsia.

Authors:  Jean F Regal; Richard M Burwick; Sherry D Fleming
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

Review 3.  Use of Race, Ethnicity, and National Origin in Studies Assessing Cardiovascular Risk in Women With a History of Hypertensive Disorders of Pregnancy.

Authors:  Amy Johnston; Victrine Tseung; Sonia R Dancey; Sarah M Visintini; Thais Coutinho; Jodi D Edwards
Journal:  CJC Open       Date:  2021-08-20

4.  Risk of future cardiovascular diseases in different years postpartum after hypertensive disorders of pregnancy: A systematic review and meta-analysis.

Authors:  Jarawee Sukmanee; Tippawan Liabsuetrakul
Journal:  Medicine (Baltimore)       Date:  2022-07-29       Impact factor: 1.817

5.  Provoking factors for postpartum chronic hypertension in women with preceding gestational hypertension/preeclampsia: A longitudinal cohort study of 22,798 pregnancies.

Authors:  Kuo-Hu Chen; Li-Ru Chen
Journal:  Int J Med Sci       Date:  2020-02-10       Impact factor: 3.738

6.  Persistent hypertension after preeclampsia in a group of Cameroonians: Result of a cross-sectional study and perspectives to reduce its burden in Limited Income Countries.

Authors:  Chris Nadège Nganou-Gnindjio; Denise Kenmogne; Doris Bibi Essama; Jan Rene Nkeck; Nathan Yanwou; Pascal Foumane
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-05-07       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.